ArticleBlood advances2023
van Rhee F, Rosenthal A, Kanhai K, et al. Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease. Blood Adv. 2022;6(16):4773-4781.
PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.